Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure
Scott D. Solomon(Brigham and Women's Hospital), Mikhail Kosiborod(AstraZeneca (Brazil)), Xiaowen Wang(Brigham and Women's Hospital), Steen Z. Abildstrøm(Novo Nordisk (Denmark)), John W. Ostrominski(Brigham and Women's Hospital), Javed Butler(Jackson Memorial Hospital), Tuvia Ben‐Gal(Tel Aviv University), Mette Nygaard Einfeldt(Novo Nordisk (Denmark)), Barry A. Borlaug(Mayo Clinic), Julio Núñez(Centro de Investigación Biomédica en Red), Dennis Wolf(University Medical Center Freiburg), Hiroshi Ito(University of Tsukuba Hospital), Walter P. Abhayaratna(Australian National University), Dalane W. Kitzman(Wake Forest University), Michele Senni(Inserm), Fozia Ahmed(Keele University), Vijay Chopra(Max Super Speciality Hospital), Melanie J. Davies(NIHR Leicester Biomedical Research Centre), Béla Merkely(Semmelweis University), Subodh Verma(St. Michael's Hospital), Peter van der Meer(University Medical Center Groningen), Sanjiv J. Shah(Northwestern University), Søren Rasmussen(Novo Nordisk (Denmark)), Mark C. Petrie(British Heart Foundation)
Cited by 113
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k